Attovia Therapeutics Reports Q2 2026 Financial Results

What Happened

• Attovia Therapeutics, Inc. announced and furnished a press release reporting its financial results for the quarter ended June 30, 2026. The press release was issued and the Current Report on Form 8-K was filed on September 2, 2026 (Exhibit 99.1).
• The 8-K itself references the press release for the detailed quarterly results; the filing was signed by Tao Fu, Chief Executive Officer.

Key Details

• Event: Filed Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on September 2, 2026.
• Period covered: Second quarter ended June 30, 2026.
• Disclosure: Press release announcing quarterly results is furnished as Exhibit 99.1 to the 8-K.
• Signature: Report signed by Tao Fu (CEO, President and Director).

Why It Matters

• Quarterly results are a primary source for investors to evaluate Attovia’s recent revenue, expenses, cash position and operational progress; the press release (Exhibit 99.1) is the place to find those specific figures and any management commentary.
• Review the attached press release for actual earnings, revenue, guidance or cash/runway updates—these items can affect the stock price and investor decisions.